How HIV and Its Treatment Disrupt the Growth Hormone Axis — And Why Tesamorelin Was Approved
HIV and antiretroviral therapy disrupt the GHRH-GH-IGF1 peptide axis through two distinct mechanisms — suppressed GH in lipodystrophy and GH resistance in wasting — with the GHRH analog tesamorelin approved to treat the lipodystrophy form.
Quick Facts
What This Study Found
Two distinct disruptions of the GHRH-GH-IGF1 axis occur in HIV/AIDS:
1. HIV lipodystrophy (associated with HAART): Suppressed GH production due to increased somatostatin tone, decreased ghrelin, elevated free fatty acids, and insulin resistance. Results in chronic inflammation, lipid abnormalities, and excess abdominal fat.
2. AIDS wasting syndrome: Elevated GH but low IGF-1 levels, indicating GH resistance — the body produces growth hormone but cannot respond to it properly.
Tesamorelin, a GHRH analog, is the only FDA-approved treatment for HIV-associated lipodystrophy, working by restoring GH pulsatility to reduce visceral adipose tissue.
Key Numbers
How They Did This
This is a narrative review article summarizing the pathophysiology of growth hormone axis disruption in HIV/AIDS, drawing on published clinical and mechanistic research.
Why This Research Matters
HIV-associated lipodystrophy affects a significant proportion of people on antiretroviral therapy and carries real cardiovascular risk from excess visceral fat, insulin resistance, and lipid abnormalities. Understanding the peptide hormone mechanisms involved — somatostatin, ghrelin, GHRH, GH, and IGF-1 — explains why tesamorelin works and guides management of these metabolic complications.
The Bigger Picture
Tesamorelin's approval in 2010 represented a milestone in peptide therapeutics — it's the only GHRH analog approved for clinical use. This review contextualizes why it works by explaining the specific peptide hormone disruptions in HIV lipodystrophy. The broader lesson is that understanding the precise mechanism of endocrine disruption is essential for choosing the right peptide-based intervention.
What This Study Doesn't Tell Us
As a review article, this doesn't present original data. Published in 2013, some treatment paradigms and antiretroviral regimens discussed may have evolved. The review notes that long-term clinical data on tesamorelin was still needed at the time of writing. Individual patient responses to GH axis disruption vary significantly.
Questions This Raises
- ?Has long-term data on tesamorelin confirmed its cardiovascular safety in HIV lipodystrophy patients?
- ?Could newer antiretroviral regimens cause less growth hormone axis disruption than older HAART protocols?
- ?Would GH secretagogues or ghrelin agonists offer alternative approaches to treating HIV lipodystrophy?
Trust & Context
- Key Stat:
- Tesamorelin: only FDA-approved GHRH analog Approved for HIV-associated lipodystrophy, it restores growth hormone pulsatility to reduce dangerous visceral fat accumulation caused by antiretroviral therapy
- Evidence Grade:
- This is a review article summarizing established pathophysiology and clinical evidence. It synthesizes existing data rather than presenting new research, providing a strong educational overview.
- Study Age:
- Published in 2013, this review covers the foundational understanding of GH axis disruption in HIV. While core mechanisms remain valid, newer antiretroviral regimens and updated long-term tesamorelin data have since become available.
- Original Title:
- Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.
- Published In:
- Reviews in endocrine & metabolic disorders, 14(2), 113-8 (2013)
- Authors:
- Jain, Shobhit, Desai, Ninad, Bhangoo, Amrit
- Database ID:
- RPEP-02197
Evidence Hierarchy
Frequently Asked Questions
Why does HIV treatment cause belly fat accumulation?
Certain antiretroviral medications disrupt the growth hormone system — they increase somatostatin (which suppresses GH), decrease ghrelin (which stimulates GH), and cause insulin resistance. The resulting low growth hormone levels lead to excess visceral (belly) fat accumulation, a condition called HIV lipodystrophy.
How does tesamorelin work differently from regular growth hormone?
Instead of replacing growth hormone directly, tesamorelin is a GHRH analog — it mimics the brain's natural signal that tells the pituitary gland to produce GH. This restores the body's normal pulsatile GH release pattern, which is considered safer and more physiological than injecting growth hormone itself.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02197APA
Jain, Shobhit; Desai, Ninad; Bhangoo, Amrit. (2013). Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.. Reviews in endocrine & metabolic disorders, 14(2), 113-8. https://doi.org/10.1007/s11154-013-9245-9
MLA
Jain, Shobhit, et al. "Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.." Reviews in endocrine & metabolic disorders, 2013. https://doi.org/10.1007/s11154-013-9245-9
RethinkPeptides
RethinkPeptides Research Database. "Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS..." RPEP-02197. Retrieved from https://rethinkpeptides.com/research/jain-2013-pathophysiology-of-ghrhgrowth-hormoneigf1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.